Expression of miR-630 associated with tyrosine kinase inhibitor therapeutic response in lung adenocarcinoma cases

Affiliations

Editorial

Srijit Das. J Thorac Dis. 2019 Mar.

. 2019 Mar;11(Suppl 3):S253-S255.

doi: 10.21037/jtd.2019.01.92.

¹ Department of Anatomy, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.

No abstract available

Conflict of interest statement

Conflicts of Interest: The author has no conflicts of interest to declare.

A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop.
Wu DW, Wang YC, Wang L, Chen CY, Lee H. Wu DW, et al. Theranostics. 2018 Feb 2;8(5):1256-1269. doi: 10.7150/thno.22048. eCollection 2018. Theranostics. 2018. PMID: 29507618 Free PMC article.

1. Wu DW, Wang YC, Wang L, et al. A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop. Theranostics 2018;8:1256-69. 10.7150/thno.22048 - DOI - PMC - PubMed
1. Eoh KJ, Lee SH, Kim HJ, et al. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis. Biochem Biophys Res Commun 2018;497:513-20. 10.1016/j.bbrc.2018.02.062 - DOI - PubMed
1. Dawson MI, Fontana JA. The peptidomimetic, 1-adamantyl-substituted, and flex-het classes of retinoid-derived molecules: structure-activity relationships and retinoid receptor-independent anticancer activities. Mini Rev Med Chem 2010;10:455-91. 10.2174/138955710791384045 - DOI - PubMed
1. Cao JX, Lu Y, Qi JJ, et al. MiR-630 inhibits proliferation by targeting CDC7 kinase, but maintains the apoptotic balance by targeting multiple modulators in human lung cancer A549 cells. Cell Death Dis 2014;5:e1426. 10.1038/cddis.2014.386 - DOI - PMC - PubMed
1. Galluzzi L, Morselli E, Vitale I, et al. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 2010;70:1793-803. 10.1158/0008-5472.CAN-09-3112 - DOI - PubMed